38 results about "Viral Genes" patented technology

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleic acids, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

The disclosure relates to block copolymer nanoparticles for therapeutic delivery of nucleotides, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering miRNAs.

Disclosed is a method of differentiating empty capsids from full capsids or loaded and unloaded non-viral gene therapy vectors in a viral preparation. The method comprises the steps of: a) providing a preparation of viral particles or gene therapy vectors; b) subjecting the preparation to interferometric scattering mass cytometry (ISCAMS) in an interferometric scattering microscope to generate mass distribution data of the viral particles; c) determining from the mass distribution data the level of empty capsids and capsids containing genomes or the level of loaded and unloaded vectors in the viral particles.

Non-viral gene therapy treatments have a number of advantages over viral vectors including typical non-antigenicity, low manufacturing cost, simplicity, and efficiency of delivering genetic cargo into the cytoplasm. The potency of non-viral gene therapy systems can be enhanced by providing them with means to more efficiently transport the delivered DNA from the cytoplasm to the nucleus. Provided herein, at least in part, are means of enhancing potency of non-viral gene therapies by including novel nuclear translocation enhancing sequences and compositions that can result in optimized nuclear translocation as well as related compositions and methods.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

Herein is reported a method for producing recombinant adeno-associated viral particle preparation (rAAVp) comprising the step of cultivating a mammalian cell comprising expression cassettes for a non-adeno-associated viral gene, which is interspaced between two AAV inverted terminal repeats (ITRs), an adeno-associated virus rep gene, an adeno-associated virus cap gene, an adeno-associated virus E1A gene, an adeno-associated virus E1B gene, an adeno-associated virus E2A gene, an adeno-associated virus E4orf6 and an adeno-associated virus VA RNA gene, and thereby producing the rAAVp, wherein the cultivating is at a pH value in the range of and including pH 7.4 to pH 7.6. The yield of the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 is higher than the yield of a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2 and the rAAVp produced by the cultivating at a pH value in the range of and including pH 7.4 to pH 7.6 has a higher percentage of full particles than a rAAVp produced by a cultivating at a pH value in the range of and including pH 7.0 to pH 7.2.

The present invention relates to oncolytic vaccinia viruses and recombinant viruses and methods of use thereof. In particular, the present invention provides a cloned vaccinia virus strain exhibiting enhanced anti-tumor properties and / or reduced immunogenicity, as well as a recombinant vaccinia virus derived therefrom. The present invention also provides recombinant oncolytic virus strains comprising an inactivated mutation in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses (e.g., vaccinia viruses, including recombinant vaccinia viruses) provided herein are useful as oncolytic viral therapies (e.g., oncolytic vaccinia viral therapies) for the treatment of cancer. The invention also provides pharmaceutical compositions of the virus, such as vaccinia virus, and methods and uses of the virus, such as vaccinia virus, for the treatment of cancer, as well as nucleic acids encoding the virus.

This disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a gene cassette encoding a target sequence. In some embodiments, the target sequence encodes a microRNA and / or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and / or the second ITR is an ITR of a non-adeno-associated virus (AAV). This disclosure also provides methods of treating a metabolic liver disorder in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide so encoded.

This invention relates to oncolytic vaccinia viruses, recombinant viruses thereof, and methods of use. Specifically, the invention provides vaccinia virus clone lines and recombinant vaccinia viruses derived therefrom, said vaccinia virus clone lines exhibiting enhanced antitumor properties and / or reduced immunogenicity. The invention also provides recombinant oncolytic virus lines comprising inactivating mutations in one or more viral genes, and / or one or more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses provided by this invention (such as vaccinia viruses, including recombinant vaccinia viruses) can be used as oncolytic virus therapies (such as oncolytic vaccinia virus therapy) for the treatment of cancer. The invention also provides pharmaceutical compositions of viruses (such as vaccinia viruses), methods and uses of viruses (such as vaccinia viruses) for the treatment of cancer, and nucleic acids encoding said viruses.

The invention discloses a cationic polymer gene delivery vector as well as a preparation method and application thereof, and the cationic polymer gene delivery vector is a polymer prepared from monomers with different hydrophilic and hydrophobic properties and polyglycidyl amine in two modes of block copolymerization and random copolymerization. The monomer polymerized with the polymer is at least one of propylene oxide, epoxybutane, epoxypentane, epoxyhexane, epoxyheptane and styrene oxide; wherein the number of the hydrophobic unit units in all repetitive units of the polymer accounts for 10%-50%. The cationic polymer gene delivery vector provided by the invention, as a non-viral gene transfection vector, has relatively low cytotoxicity and relatively good gene transfection capability.

The present invention relates to a chimeric poxvirus with improved anticancer activity (higher cancer cell killing capacities and better tumor selectivity), as well as variant version thereof with one or more altered viral genes, recombinant versions thereof comprise one or more nucleic acid(s) of interest and recombinant variant versions thereof, all of which may be included in a composition and used for the treatment of a disease, in particular proliferative disease, notably cancers.

The invention discloses an application of etoposide in preparation of anti-rabies virus drugs, and proves that the clinical anti-tumor drug etoposide has remarkable anti-rabies virus activity on cell and animal levels for the first time, and plays an antiviral role in vitro and vivo by inhibiting virus replication and reducing virus gene and protein expression. The invention provides a brand-new medical application for etoposide, namely provides a new medicine and a technical scheme for preparing a rabies virus, and has important significance for solving the problem of clinical treatment of rabies.

The present invention provides an apparatus, method, and system for measuring the attributes of a viral gene delivery vehicle sample through isolation. [Solution] In one embodiment, the method, system, and computer program product perform a series of logical operations to analyze a viral gene delivery vehicle sample in a set of analytical instruments including at least one separation instrument, at least one static light scattering instrument, and at least two concentration detectors, thereby determining the capsid protein mass of the sample m A And the sample modification factor mass m B And the molar mass M of the modifying factor in the sample B This results in the molar mass of the capsid protein in the sample M A The data source receives the molar mass of the capsid protein, the injection volume v of the sample from the injection volume data source, and the total VGDV particle concentration C of the sample. A This includes performing a series of logical operations to calculate [something].

The present disclosure provides, for instance, polymer-lipid hybrid nanoparticle compositions and methods of making and using them. The polymer-lipid hybrid nanoparticle may comprise, for example, poly(lactic-co-glycolic) acid (PLGA), polyethylenimine (PEI), and D-Lin-MC3-DMA (MC3). The polymer-lipid hybrid nanoparticle can be used to deliver, for example, nucleic acids and small molecules, cells.

The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

To provide a VLP vaccine derived from the genus Enterovirus which is safe and has good stability.SOLUTION: The VLP vaccine of the present invention is highly safe because it uses VLPs having no viral internal gene as an antigen, and has good stability because it is fixed with formaldehyde in a high salt concentration.SELECTED DRAWING: None

The present application relates to the technical field of biomedical materials, in particular to a non-viral gene carrier and a preparation method and application thereof. The non-viral gene carrier prepared by EDC / NHS cross-linking reaction of baicalin and polyethyleneimine can be used for gene delivery and preparation of a gene therapy drug. The present application further provides a nano-complex composed of the non-viral gene carrier and nucleic acid, which can be used for gene delivery and preparation of a gene therapy drug. The nano-complex can not only effectively deliver target genes into cells, but also synergize miR-34a and baicalin to jointly exert an anti-tumor effect, greatly enhancing the anti-tumor treatment efficacy.

The disclosure relates to block copolymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods thereof. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides.

The invention provides application of WAY-311318 in preparation of an anti-pseudorabies virus product, and belongs to the technical field of pseudorabies prevention and treatment. The invention proposes that the WAY-311318 has an anti-pseudorabies virus effect for the first time. The WAY-311318 disclosed by the invention shows a remarkable inhibition effect on multiple aspects such as viral gene transcription, protein synthesis and infection efficiency, and can inhibit replication and release of the pseudorabies virus, so that targeted epigenetic regulation can become a new strategy for preventing and controlling the PRV.

A method of producing a cell line for production of a gene therapy vector includes providing a cell line (10) suitable for production of a gene therapy vector (20); editing the genome (12) of the cell line (10), for example using CRISPR gene editing, to remove at least one region of nucleic acid sequence, wherein the region of nucleic acid sequence is unwanted in the gene therapy vector (20) to be produced thereby; and confirming deletion of the region of nucleic acid sequence from the genome (12') of the modified cell line (10'). The region of unwanted nucleic acid sequence may be derived from a virus. The modified cell line (10) can be used to make a viral gene therapy vector (20) that does not contain unwanted nucleic acid sequences.

Oncolytic HSV vectors comprising NF-κB response elements or Oct-3 / 4-SOX2 response elements in the regulatory regions of viral genes that affect the efficiency of viral replication.

This invention discloses an adeno-associated virus (AAV) mutant fused with a cell-penetrating peptide and its applications. The invention also discloses an AAV capsid protein mutant or a functional fragment thereof, which, compared to the amino acid sequence of the parental or wild-type AAV capsid protein, has an inserted amino acid sequence of a cell-penetrating peptide into the amino acid sequence of the parental or wild-type AAV capsid protein. The AAV mutant fused with the cell-penetrating peptide comprises the AAV capsid protein mutant or its functional fragment. This invention directly inserts the cell-penetrating peptide into the AAV capsid protein via fusion expression, firmly fusing the peptide into the AAV capsid protein. This significantly improves the AAV's ability to transfect cells and its transduction efficiency, as well as gene expression efficiency, reducing the amount of virus required and thus reducing immunogenicity. This will facilitate the application of AAV viral gene vectors in gene therapy.

This invention discloses a TBT1 protein, a resistance gene, a molecular marker, and their applications for enhancing resistance to ToBRFV, belonging to the field of plant resistance gene technology. This invention also identified a novel gene on chromosome 11 of tomato that exhibits resistance to ToBRFV. TBT1 Overexpression in tomatoes TBT1 It can significantly enhance resistance to brown wrinkled fruit virus. Compared to disease-resistant genes, the disease-resistant gene of this invention... TBT1 This invention avoids exerting selective pressure on the virus, effectively preventing viral gene evolution from overcoming resistance and achieving long-term stable disease resistance. It addresses the technical pain points of existing disease resistance genes being prone to loss of resistance and requiring frequent variety updates. Furthermore, this invention has developed two related to disease resistance genes. TBT1 The tightly linked molecular markers of this invention can be used to detect and identify resistance genes for tomato brown wrinkle fruit virus disease. This method can be used in a simple, fast, and high-throughput manner in breeding practice, thus accelerating the process of disease-resistant tomato breeding.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an influenza A viral genome. The influenza A viral (IAV) RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an influenza A viral genome at targeted portions of the genome that are conserved across a variety of known influenza A viral genome variants, and are therefore capable of inhibiting expression of various influenza A virus strains. Pharmaceutical compositions that include one or more IAV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described IAV RNAi agents to pulmonary cells, in vivo, provides for inhibition of influenza A viral genome expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases, disorders, and / or symptoms caused by influenza A viral infection.

The invention discloses a Klotho mRNA lipid nanoparticle, a preparation method thereof and an application of the Klotho mRNA lipid nanoparticle in anti-aging. The method comprises the following steps: S1, respectively preparing a water phase solution containing Klotho mRNA and an organic phase solution containing a lipid mixture; s2, mixing the aqueous phase solution and the organic phase solution according to a preset flow velocity ratio by using a microfluidic mixing device, and forming a lipid nanoparticle precursor solution through self-assembly; s3, performing multi-stage dialysis treatment on the lipid nanoparticle precursor solution, replacing a buffer system and removing a residual solvent; and S4, concentrating the dialyzed solution, so as to obtain the Klotho mRNA lipid nanoparticles. According to the invention, a lipid nanoparticle (LNP) delivery platform is combined with mRNA (messenger Ribonucleic Acid) for coding secreting type Klotho protein for the first time, and a non-viral gene medicinal preparation for systemic anti-aging intervention is creatively developed.

During the production of replication-defective viral gene therapy vectors, random mutations or other events can produce unwanted replication-competent viruses ("RCVs"). Viral gene therapy vector producers therefore assay for the presence of contaminating RCVs by assaying for serial infection, i.e., transducing target cells with a viral vector, then lysing the transduced cells, and then mixing the lysate with live assay cells, and then microscopically observing the assay cells to visually determine if they have been infected with virus. We have tested various alternative approaches, and surprisingly found that droplet digital PCR not only is faster than the prior art approaches, but is an order of magnitude more sensitive, capable of detecting as few as seven (7) replication-competent adenoviruses ("RCs") in, for example, 3 x 1010 assay cells.

The application discloses a polymer containing a chemotherapy drug SN38 and a macrocyclic polyamine, and a preparation method and application thereof, and belongs to the technical field of polymers.The polymer containing the chemotherapy drug SN38 and the macrocyclic polyamine can release the SN38 under esterase conditions; can effectively condense siRNA to form uniform spherical nanoparticles; the nanoparticles formed by compounding with auxiliary lipids (DSPE-PEG-iRGD) have excellent tumor targeting and selectivity; under hypoxic conditions, the gene transfection capacity can be improved through a photochemical internalization effect to promote lysosome escape, and the knockdown rate of Bcl-2 protein is as high as 76%; the proliferation of HCT116 cells in the mouse body is significantly inhibited through delivery of Bcl-2 siRNA and photodynamic therapy, and the tumor inhibition rate is as high as 95%. The polymer can be used for preparing a non-viral gene carrier, as a photosensitizer, and for preparing a carrier for delivering the chemotherapy drug SN38 in tumor treatment.

Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and / or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and / or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.

The invention discloses preparation and application of a gold cluster compound of a non-viral targeted in-vivo gene delivery vector, and relates to the field of application of non-viral gene delivery vectors. Au and a specific ligand protamine and Ang-2 peptide have a synergistic effect to form a cluster compound, and the molar ratio of Au to Pro to Ang-2 is 17: 25: (10-40), preferably 17: 25: 34. Mixing the gold salt solution with the ligand to form a mixed solution; under the conditions of certain temperature and pH, the mixed solution system is subjected to a reduction reaction, high-valence Au ions in the gold salt are reduced into Au atoms or monovalent Au ions, and Au forms a gold cluster compound through physical or chemical interaction; the sulfydryl-containing ligand is polypeptide or protein with better biocompatibility, and the cluster compound disclosed by the invention can be used for successfully delivering nucleic acid into cells and has good biocompatibility.